I had another thought about the trial. Why is the required patient level still only 394? Could it be that the FDA has agreed to consider the open label patients like the MHRA is doing and that's why the trial has now been modified to include them? I believe Pourhassan stated there were some patients that were enrolled in CD12 but then didn't participate, and we had 45 OLE's as of the last conference call. We could be getting the EUA just based on the ones we already have. Your thoughts?